Loading ...
The researchershave designedan antibody - based therapy
the potentialto influenceantibody - based therapies
the waythat ... are discoveredantibody - based therapies
New Study RevealsHow ... LedAntibody Treatment
to target and block the production of a specific protein inside the body that contributes to psoriasis(passive) are designedAntibody treatments
to specifically target cancer in dogs using molecular biological tools to be species - specific antibodies that bind to specific target cell - surface antigens(passive) are designedTherapeutic Monoclonal Antibodies
The companydiscoversmonoconal antibody
because it enabled himto discoverantibody therapy
by TNF - independent gut inflammation(passive) caused byantibody therapy
the babyleadsAntibody therapy
A companydiscoveringtherapeutic antibodies
technologiesto discovertherapeutic antibodies
to block surface receptor cutting off the tumor promoting activity of the target(passive) are often designedTherapeutic antibodies
the wayare discoveredtherapeutic antibodies
The preparation and design of antigen ... requiredto discovertherapeutic antibodies
for example(passive) are ... designedTherapeutic antibodies
to more selectively target cancer cells(passive) is designedMonoclonal antibody therapy
The successto discoverthe therapeutic antibodies
requiredto discovertherapeutic antibodies
to reduce vascular inflammation(passive) are designedThe therapeutic antibodies
by Compugen(passive) originally discovered bytherapeutic antibodies
utilizing a proprietary human memory B cell platformto discoverantibody therapeutics
Scientists can apply for access to their cutting - edge technologiesto discovertherapeutic antibodies
which structural computational methodsto designantibody therapeutics
North Coast Biologicsdiscoverstherapeutic antibodies
Significant opportunities ... to date it has been challengingto discovertherapeutic antibodies
through hybridoma or display technologies , identification of target - specific TCRs(passive) are ... discoveredtherapeutic antibodies
We take advantage of the universal HybriFree antibody discovery engineto ... discovertherapeutic antibodies
Diamond ... a good wayto designtherapeutic antibodies
by passive transfusion of cognate antibodies and(passive) is caused byAntibody mediated
by the passive infusion of antibodies from the donor reacting with the cognate antigen of the recipient(passive) is caused byAntibody mediated
Following dosing unpredictability still reigns and mutations in the hinge of the antibody which may prevent Fab - arm exchange in - vivo should be consideredwhen designingtherapeutic antibodies
Polysorbates in the Products(passive) Are Caused ByMonoclonal Antibody Therapies
y robertcontributeantibody - coated
chemiluminscence ( 4(passive) was discovered byAntibody presenting
to block the functional activity of SEMA4D.(passive) is designedVX15 antibody
Thus , careful engineering of the Fc region should be consideredwhen designingmonoclonal antibody therapeutics
of two heavy ( H ) and two light ( L ) chains(passive) is composedantibody
by the formation of complexes of antigen with antibody or by transient suppression of antibody synthesis(passive) caused byantibody
by enzyme - linked immunosorbent assay ( ELISA(passive) discovered byantibody
to level of resistance to these therapiesleadingto level of resistance to these therapies
to level of resistanceleadingto level of resistance
in long - term viral suspension in HIV infectionhas resultedin long - term viral suspension in HIV infection
in patients undergoing prolonged treatment with biologics , such as enzyme replacement or antibody - based therapiesprovokedin patients undergoing prolonged treatment with biologics , such as enzyme replacement or antibody - based therapies
to target these cellsdesignedto target these cells
in improved survival of patientshas resultedin improved survival of patients
to enable endogenous regenerationdesignedto enable endogenous regeneration
to enhance ADCCis designedto enhance ADCC
in improved survival of patients ( 28has resultedin improved survival of patients ( 28
to attach to specific proteins in a cancer cell 3 IMMUNE SYSTEMdesignedto attach to specific proteins in a cancer cell 3 IMMUNE SYSTEM
the coming decade of cancer carewill strongly influencethe coming decade of cancer care
to clinical improvement in breast cancer patientsledto clinical improvement in breast cancer patients
to sustained remission of HIV - like virus Researchledto sustained remission of HIV - like virus Research
to sustained remission of HIV - like virus |ledto sustained remission of HIV - like virus |
to sustained remission of HIV - like virusledto sustained remission of HIV - like virus
to lasting HIV - like virus remissionledto lasting HIV - like virus remission
to sustained remission of HIV - likeledto sustained remission of HIV - like
to lasting HIV - like virusledto lasting HIV - like virus
in functional changes on a per - cell basismay resultin functional changes on a per - cell basis
in an 11 % greater strength increaseresultedin an 11 % greater strength increase
in increasedresultedin increased
to increasedledto increased
to sustained remission of HIV - like virus NIH researchledto sustained remission of HIV - like virus NIH research
to survivalmay contributeto survival
to sustained remission of HIV - like virus NIHledto sustained remission of HIV - like virus NIH
alsoledalso
alsocausesalso
to attack the virusdesignedto attack the virus
in massive expansion of virus - specific CD8(+ ) T cellsresultedin massive expansion of virus - specific CD8(+ ) T cells
to survival.[12may contributeto survival.[12
to lastingledto lasting
to survival.[22may contributeto survival.[22
to depletion of Tregledto depletion of Treg
in a clear paradigm shift in MS therapeuticsresultedin a clear paradigm shift in MS therapeutics
in better outcomesresultedin better outcomes
in the remedy not becoming efficientresultsin the remedy not becoming efficient
to depletion of Treg in both the tumor and the peripheryledto depletion of Treg in both the tumor and the periphery
in partial protection from EAE ( 6resultedin partial protection from EAE ( 6
in depletion of > 95 % of the respective T - cell subsetsresultedin depletion of > 95 % of the respective T - cell subsets
to rapid normalization of plaque - induced neuritic alterationsleadsto rapid normalization of plaque - induced neuritic alterations